Zydus Receives Health Canada Approval for Mesalamine Suppositories
Zydus Lifesciences Limited has received a Notice of Compliance (NOC) from Health Canada for generic Mesalamine suppositories 1000 mg.
Mesalamine suppositories are indicated for the treatment of active ulcerative proctitis.
Earlier, Zydus also received NOC from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg, which are used to treat hypothyroidism.
Zydus Lifesciences Ltd. is a global lifesciences company that develops, manufactures, and markets a range of healthcare therapies.
No additional quotes available.
Author's summary: Zydus gets Health Canada approval for Mesalamine suppositories.
More News
- Numbers/facts about tonight’s Breeders Crown
- Sault's new website is missing parts
- Mattingly’s Revenge Hounds Dodgers In World Series Vs. Blue Jays
- Godby's senior QB Lazarus Chambers drops 4 TDs in his 1st start to stun Lincoln | Takeaways
- Weekly roundup: Toyota spins off Century, Dream Motor buys Montgomery Lexus, Auto delinquencies hit record high
- Sheridan WYO Rodeo 2025 stock contractors earn national honors and WNFR selections
- Compulsory voting: A remedy or ruse for democracy? - Institute of Development Studies
- Breeders Crown analysis and selections
- Sheridan County students showcase skills in band and choir clinic